TRYNGOLZA

Oct 16, 2026

Summary siRNA and ASOs are emerging as major RNA-based therapeutic platforms, enabling targeted disease treatment by silencing or modulating gene expression. siRNA holds a commercial advantage in revenue generation and dosing convenience. Marketed siRNA drugs generated approximately $4.2 billion in disclosed...

Jun 29, 2026

Summary Over 3 million Americans live with sHTG, including around 1 million high-risk patients with triglycerides ≥880 mg/dL or ≥500 mg/dL plus a history of acute pancreatitis or other comorbidities. In June 2026, the FDA approved Ionis’ TRYNGOLZA (already approved for FCS in 2024) as the first and only trea...

Nov 28, 2025

Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA’s approval of REDEMPLO (plozasiran) on November 18, 2025—marking the company’s first FDA-approved medicine and the first-ever FDA-approved siRNA therapeutic for familial chylomicronemia syndrome (FCS) treatment. This historic approval r...